SCHEMBL6849680

SCHEMBL6849680

O=C(Cc1ccc(Cl)cc1)NC1CCc2[nH]cnc2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
POLB P06746 2/20 0.52
GRM7 Q14831 1/20 0.50
SIGMAR1 Q99720 1/20 0.45
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
CDK1 P06493 1/20 0.41
CDK2 P24941 1/20 0.41
MAPK1 P28482 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
ATF4 P18848 1/20 0.40
P2RX7 Q99572 2/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 1/20 0.38
RET P07949 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846858 0.90 LMNA (0.43) LMNAPOLBGRM7ATF4P2RX7
SCHEMBL6846909 0.88 LMNA (0.45) LMNAPOLBGRM7ATF4MTNR1A
Hydrochloric Acid SCHEMBL7096357 0.87 LMNA (0.44) LMNAPOLBGRM7MTNR1AMTNR1B
SCHEMBL6850768 0.83 MEN1 (0.44) LMNANPC1RAB9AKMT2A
SCHEMBL6849610 0.83 LMNA (0.43) LMNAPOLBGRM7TP53MAPT
SCHEMBL6846977 0.79 POLB (0.50) LMNAPOLBTP53MAPTMAPK1
SCHEMBL6846975 0.79 POLB (0.50) LMNAPOLBTP53MAPTMAPK1
SCHEMBL6850893 0.76 KMT2A (0.49) POLBP2RX7MTNR1AMTNR1BNPC1
SCHEMBL6851432 0.75 P2RX7 (0.38) P2RX7NPC1RAB9AKMT2AHPGD
SCHEMBL6849677 0.75 L3MBTL1 (0.43) LMNAPOLBTP53MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 LMNA 4098/4885POLB 4423/4885GRM7 654/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 LMNA 4098/4885POLB 4423/4885GRM7 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.